Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ARTBIO","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"NORWAY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ARTBIO","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"NORWAY","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"ARTBIO","sponsor":"SpectronRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy AB001 for Indiana and Surrounding States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"NORWAY","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"ARTBIO","sponsor":"PharmaLogic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"NORWAY","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"ARTBIO","sponsor":"Nucleus RadioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"NORWAY","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"ARTBIO","sponsor":"FogPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FogPharma and ARTBIO Collaborate on Alpha-Particle Radioligand Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"NORWAY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by ARTBIO

    Menu

    ARTBIO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ARTBIO

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Norway
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              FogPharma and ARTBIO Collaborate on Alpha-Particle Radioligand Therapies

              Details:

              The collaboration aims to co-develop Helicon-enabled 212Pb alpha radioligand therapies by leveraging FogPharma’s field-leading Helicon platform and ARTBIO’s AlphaDirect™ platform, for cancer.

              Lead Product(s): 212Pb Alpha Radioligand Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: FogPharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 14, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ARTBIO

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Norway
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials

              Details:

              Under the terms of the agreement, Nucleus will manufacture ARTBIO’s 212Pb-radiolabeled therapies for its planned Phase I and II clinical trials of its lead program in prostate cancer, AB001 (212Pb-NG001), using ARTBIO’s proprietary AlphaDirectTM 212Pb isolation technology.

              Lead Product(s): 212Pb-NG001

              Therapeutic Area: Oncology Product Name: AB001

              Highest Development Status: Phase I Product Type: Peptide

              Recipient: Nucleus RadioPharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 07, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ARTBIO

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Norway
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States

              Details:

              Under the agreement, PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 (212Pb-NG001), using ARTBIO's proprietary AlphaDirect™ 212Pb isolation technology.

              Lead Product(s): 212Pb-NG001

              Therapeutic Area: Oncology Product Name: AB001

              Highest Development Status: Phase I Product Type: Peptide

              Recipient: PharmaLogic

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 12, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ARTBIO

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Norway
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy AB001 for Indiana and Surrounding States

              Details:

              The partnership aims to produce a novel prostate cancer therapy known as AB001 (212Pb-NG001), a promising therapy for prostate cancer, by utilizing SpectronRx's expertise and state-of-the-art facilities.

              Lead Product(s): 212Pb-NG001

              Therapeutic Area: Oncology Product Name: AB001

              Highest Development Status: Phase I Product Type: Peptide

              Recipient: SpectronRx

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership January 09, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ARTBIO

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Norway
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies

              Details:

              The proceeds will be used to help solidify ARTBIO's proprietary Pb212 isolation technology AlphaDirect™ and its distributed manufacturing network, advance its lead program AB001 (212Pb-NG001) in the clinic for treatment of prostate cancer, and further the company's pipeline.

              Lead Product(s): 212Pb-NG001

              Therapeutic Area: Oncology Product Name: AB001

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Third Rock Ventures

              Deal Size: $90.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing December 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ARTBIO

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Norway
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential

              Details:

              The financing enables ARTBIO's ongoing clinical development of its lead program AB001 (212Pb-NG001) for the treatment of prostate cancer and will advance its AlphaDirect™ Pb212 isolation technology.

              Lead Product(s): 212Pb-NG001

              Therapeutic Area: Oncology Product Name: AB001

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: F-Prime Capital

              Deal Size: $23.0 million Upfront Cash: Undisclosed

              Deal Type: Financing June 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY